Guerbet announced that the FDA has approved Dotarem (gadoterate meglumine) injection, a gadolinium-based contrast agent (GBCA), for intravenous use with magnetic resonance imaging in the brain, spine, ...
FDA Approves Guerbet's Dotarem® (gadoterate meglumine) for Pediatric Patients Younger Than Two Years
PRINCETON, N.J., Sept. 5, 2017 /PRNewswire/ -- Guerbet LLC USA, the US affiliate of the global specialist in contrast products and solutions for medical imaging, announced today that the US Food and ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
Guerbet announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with ...
Guerbet, the contrast agent specialist for medical imaging, announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to ...
Zydus Lifesciences’ subsidiary, Zydus Lifesciences Global FZE, signed an exclusive licensing and supply agreement with Viwit Pharmaceuticals for two gadolinium-based MRI contrast agents targeting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results